Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia

Marc C. Chamberlain*, Jeffrey Raizer

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Objective: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML). Background: Alkylator-based chemotherapy is recognized to be leukemogenic; however, it is infrequently described as a delayed consequence of anti-glioma treatment. Methods: Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients). Results: Exposure to alkylator-based chemotherapy ranged from 8 to 30 months (median 24). The diagnosis of tMDS was determined by bone marrow biopsy in 7 patients. Seven patients showed chromosomal abnormalities consistent with chemotherapy induced MDS. Three patients were diagnosed with AML as well (in two determined by bone marrow and one at autopsy). Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 to 31 months (median 24 months). Two patients were treated with bone marrow transplantation and 5 received supportive care only. Five patients have died, 2 as a consequence of recurrent brain tumor, 1 as a complication of transplantation, and 2 due to AML. Conclusions: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods. Future work to determine at risk patients would be important.

Original languageEnglish (US)
Pages (from-to)229-232
Number of pages4
JournalJournal of Neuro-Oncology
Volume93
Issue number2
DOIs
StatePublished - Jan 1 2009

Keywords

  • Alkylator chemotherapy
  • Gliomas
  • Treatment-related myelodysplastic syndrome

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia'. Together they form a unique fingerprint.

  • Cite this